<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600704</url>
  </required_header>
  <id_info>
    <org_study_id>LUH 1975 AK</org_study_id>
    <secondary_id>POL 1969 TT</secondary_id>
    <nct_id>NCT00600704</nct_id>
  </id_info>
  <brief_title>Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery</brief_title>
  <official_title>Impact of Fluid Restriction Policy Added to Intra-Operative Cell Salvage in Reducing the Use of Red Cells in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larissa University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larissa University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' hypothesis is that restriction of circulating fluids in comparison to a
      liberal fluid administration policy would lead to a reduction of allogenic red blood cells
      exposure in patients undergoing cardiopulmonary bypass (CPB) for primary coronary artery
      bypass graft supported by reinfusion of washed shed blood from thoracic cavities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      192 patients operated under equal conditions were assigned prospectively and randomly either
      for a restrictive protocol for intravenous fluid administration (group A, 100 patients) or
      not (group B, 92 patients). Transfusion guidelines were common for the two groups. The
      volumes of intravenous fluids, priming, &quot;extra&quot; volume on pump and cardioplegic solution and
      the volume of urine were recorded. Net erythrocyte volume loss was calculated. The number of
      the transfused PRC was analyzed as a continuous variable. &quot;Transfusion&quot; was analyzed as a
      categorical characteristic. Analysis employed Student's two-tailed t-test, t-paired test and
      chitest.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Number of Packed Red Cells Units Transfused During Hospital Stay</measure>
    <time_frame>20 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Bypass</condition>
  <condition>Erythrocyte Transfusion</condition>
  <arm_group>
    <arm_group_label>RESTRICTED FLUIDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary Bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FREE FLUIDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Free fluid infusion unless Hb&lt; 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluid Restriction Policy</intervention_name>
    <description>Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass</description>
    <arm_group_label>RESTRICTED FLUIDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Free fluid infusion</intervention_name>
    <description>Free fluid infusion unless Hb&lt; 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass</description>
    <arm_group_label>FREE FLUIDS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ejection fraction (EF) of left ventricle (LV) &gt; 35%

          -  Preoperative serum Creatinine &lt; 150 Î¼mol/l

          -  Preoperative Haemoglobin &gt; 10/dl

          -  Peripheral anastomosis scheduled =&lt; 3

        Exclusion Criteria:

          -  redo bypass-emergency operations

          -  prior coronal stenting

          -  active congestive heart failure

          -  documented Myocardial Infraction within the previous 6 weeks

          -  NYHA class &gt; 3

          -  Carotid stenosis &gt; 50%

          -  CVA

          -  INR &gt; 1.5

          -  chronic obstructive pulmonary disease (COPD)

          -  Steroid therapy-chronic inflammatory process

          -  Use of aprotinin or tranexamic acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ATHINA KLEITSAKI, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Larissa University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GEORGE VRETZAKIS, M.D. PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cardiac Anesthesia Unit, Department of Anesthesiology, University Hospital of Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>KONSTANTINOS STAMOULIS, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiac Anesthesia Unit, Department of Anesthesiology, University Hospital of Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHRISTOS DRAGOUMANIS, M.D. PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiac Anesthesia Unit, Department of Anesthesiology, University Hospital of Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>VASILIOS TASOUDIS, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiac Anesthesia Unit, Department of Anesthesiology, University Hospital of Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>KATERINA KYRIAKAKI, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiac Anesthesia Unit, Department of Anesthesiology, University Hospital of Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DEMETRIOS MIKROULIS, M.D. PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiothoracic Surgery, University Hospital of Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ATHANASIOS GIANNOUKAS, MD MSc PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Vascular Surgery, University Hospital of Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>NIKOLAOS TSILIMINGAS, M.D. PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiothoracic Surgery, University Hospital of Larissa, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Larissa University Hospital</name>
      <address>
        <city>Larissa</city>
        <state>Thesalia</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA 2nd, Haan CK, Royston BD, Bridges CR, Higgins RS, Despotis G, Brown JR; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007 May;83(5 Suppl):S27-86. Review.</citation>
    <PMID>17462454</PMID>
  </reference>
  <reference>
    <citation>Dial S, Delabays E, Albert M, Gonzalez A, Camarda J, Law A, Menzies D. Hemodilution and surgical hemostasis contribute significantly to transfusion requirements in patients undergoing coronary artery bypass. J Thorac Cardiovasc Surg. 2005 Sep;130(3):654-61.</citation>
    <PMID>16153909</PMID>
  </reference>
  <reference>
    <citation>Stover EP, Siegel LC, Parks R, Levin J, Body SC, Maddi R, D'Ambra MN, Mangano DT, Spiess BD. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology. 1998 Feb;88(2):327-33.</citation>
    <PMID>9477051</PMID>
  </reference>
  <reference>
    <citation>Karkouti K, Djaiani G, Borger MA, Beattie WS, Fedorko L, Wijeysundera D, Ivanov J, Karski J. Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. Ann Thorac Surg. 2005 Oct;80(4):1381-7.</citation>
    <PMID>16181875</PMID>
  </reference>
  <reference>
    <citation>Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A. Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed? J Thorac Cardiovasc Surg. 2003 Jun;125(6):1438-50.</citation>
    <PMID>12830066</PMID>
  </reference>
  <reference>
    <citation>DeFoe GR, Ross CS, Olmstead EM, Surgenor SD, Fillinger MP, Groom RC, Forest RJ, Pieroni JW, Warren CS, Bogosian ME, Krumholz CF, Clark C, Clough RA, Weldner PW, Lahey SJ, Leavitt BJ, Marrin CA, Charlesworth DC, Marshall P, O'Connor GT. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 2001 Mar;71(3):769-76.</citation>
    <PMID>11269449</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <results_first_submitted>March 4, 2011</results_first_submitted>
  <results_first_submitted_qc>May 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2011</results_first_posted>
  <last_update_submitted>May 9, 2011</last_update_submitted>
  <last_update_submitted_qc>May 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>ATHINA KLEITSAKI</name_title>
    <organization>LARISSA UNIVERSITY HOSPITAL/DPT OF ANESTHESIOLOGY</organization>
  </responsible_party>
  <keyword>Allogenic Blood Use</keyword>
  <keyword>Total Blood Loss</keyword>
  <keyword>Reinfusion of Washed Shed Blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This prospective study was conducted in our University Hospital over a 20-month period, after approval from the Institution Ethics committee, and written informed consent was obtained from all patients before entering the study. All the participants were patients of the Cardio-Thoracic Clinic of our Hospital.</recruitment_details>
      <pre_assignment_details>Exclusion criteria were emergency or re-do operations, operations starting after 18.00, administration of tissue plasminogen activator (TPA) or other thrombolytic medications, pre-existing hematologic disease or coagulation abnormality, advanced cirrhosis, renal failure, preoperative blood product transfusion, combined cardiac and carotid surgery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RESTRICTED FLUIDS</title>
          <description>Infusion of Hes 130/0.4 up to 500 ml</description>
        </group>
        <group group_id="P2">
          <title>FREE FLUIDS</title>
          <description>Free fluid infusion unless Hb&lt; 6g/dl(allogenic blood use)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RESTRICTED FLUIDS</title>
          <description>Infusion of Hes 130/0.4 up to 500 ml</description>
        </group>
        <group group_id="B2">
          <title>FREE FLUIDS</title>
          <description>Free fluid infusion unless Hb&lt; 6g/dl(allogenic blood use)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="7.9"/>
                    <measurement group_id="B2" value="65.5" spread="8.3"/>
                    <measurement group_id="B3" value="65.77" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of Packed Red Cells Units Transfused During Hospital Stay</title>
        <time_frame>20 months</time_frame>
        <population>Patients between ages 18-85 undergoing elective cardiac surgery under cardiopulmonary bypass</population>
        <group_list>
          <group group_id="O1">
            <title>RESTRICTED FLUIDS</title>
            <description>Infusion of Hes 130/0.4 up to 500 ml</description>
          </group>
          <group group_id="O2">
            <title>FREE FLUIDS</title>
            <description>Free fluid infusion unless Hb&lt; 6g/dl(allogenic blood use)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Packed Red Cells Units Transfused During Hospital Stay</title>
          <population>Patients between ages 18-85 undergoing elective cardiac surgery under cardiopulmonary bypass</population>
          <units>packed red cells units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>PRC Units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.90" upper_limit="1.36"/>
                    <measurement group_id="O2" value="1.91" lower_limit="1.63" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size calculation was based on a two-sided alpha error of .05 and 80% power. After applying the protocol in two equal groups of 10 patients, the analysis showed that the study requires 60 patients per group. However, we decided to enroll up to 100 patients per group to allow for patient attrition or missing data, and also in order to look for differences with regards to transfusion between patient subgroups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.379</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.096</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.189</ci_lower_limit>
            <ci_upper_limit>0.569</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis :restrictive fluid protocol does not have any effect concerning the mean number of PRC units transfused.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.797</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.168</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.465</ci_lower_limit>
            <ci_upper_limit>1.129</ci_upper_limit>
            <estimate_desc>The mean difference between groups B and A is adjusted for age, gender, BMI and preoperative HCT, while BSA, weight, height, postoperative HCT were not included in the final model to avoid collinearity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RESTRICTED FLUIDS</title>
          <description>Infusion of Hes 130/0.4 up to 500 ml</description>
        </group>
        <group group_id="E2">
          <title>FREE FLUIDS</title>
          <description>Free fluid infusion unless Hb&lt; 6g/dl(allogenic blood use)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infraction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>persistent significant arrythmia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>low output syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>persistent neurological dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>lower extremity ischemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>reoperation for bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Athina Kleitsaki</name_or_title>
      <organization>Larissa University Hospital Dept. of Anesthesiology</organization>
      <phone>00306948481865</phone>
      <email>theoath1@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

